290 results on '"Lichtenstein, Gary R"'
Search Results
2. Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses
3. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study
4. Exposure to Intravenous Opioids Is Associated With Future Exposure to Opioids in Hospitalized Patients With Inflammatory Bowel Diseases
5. Lifetime Economic Burden of Crohn’s Disease and Ulcerative Colitis by Age at Diagnosis
6. Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases—A Clinical Practice Update: Commentary
7. Meeting Report: AGA Biosimilars Roundtable
8. The use of chromoendoscopy for surveillance of inflammatory bowel disease
9. Optimizing the quality of endoscopy in inflammatory bowel disease: focus on surveillance and management of colorectal dysplasia using interactive image- and video-based teaching
10. The TREAT Registry: Evolution of Knowledge From 1999 to 2017: Lessons Learned
11. 127 - Inflammatory Bowel Disease
12. Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Azathioprine and 6-Mercaptopurine: A Meta-analysis
13. Risk of Lymphoma in Patients With Ulcerative Colitis Treated With Thiopurines: A Nationwide Retrospective Cohort Study
14. Reliability and Initial Validation of the Ulcerative Colitis Endoscopic Index of Severity
15. Clinical Predictors of Aggressive/Disabling Disease: Ulcerative Colitis and Crohn Disease
16. No Increased Risk of Myocardial Infarction Among Patients With Ulcerative Colitis or Crohn's Disease
17. A Systematic Review of Factors That Contribute to Hepatosplenic T-Cell Lymphoma in Patients With Inflammatory Bowel Disease
18. Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis
19. Su1860 GUSELKUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE AS MEASURED BY PROMIS-29 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 3 QUASAR INDUCTION STUDY
20. Su1862 GUSELKUMAB IMPROVES SYMPTOMS OF FATIGUE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 3 QUASAR INDUCTION STUDY RESULTS AT WEEK 12
21. Su1809 ASSESSMENT OF STEROID USE IN PATIENTS WITH ACTIVE ULCERATIVE COLITIS WHO INITIATED A NEW JANUS KINASE INHIBITOR OR TUMOR NECROSIS FACTOR INHIBITOR USING DATA FROM A UNITED STATES CLAIMS DATABASE
22. Sa1950 IMPACT OF GLP1 AGONISTS ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
23. 759 THE EFFICACY AND SAFETY OF GUSELKUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR MAINTENANCE STUDY
24. 721 SAFETY AND CLINICAL EFFECTIVENESS OF GLP1 AGONISTS IN INFLAMMATORY BOWEL DISEASE PATIENTS
25. Reinduction With Certolizumab Pegol in Patients With Relapsed Crohn's Disease: Results From the PRECiSE 4 Study
26. Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months
27. Clinical Pharmacology of 5-ASA Compounds in Inflammatory Bowel Disease
28. Introduction of Clinical Practice Update Committee Articles
29. Contributors
30. Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab
31. Introduction to Clinical Practice Update Committee Articles
32. Rosiglitazone for Active Ulcerative Colitis: A Randomized Placebo-Controlled Trial
33. Risk for Active Tuberculosis in Inflammatory Bowel Disease Patients
34. Effect of Once- or Twice-Daily MMX Mesalamine (SPD476) for the Induction of Remission of Mild to Moderately Active Ulcerative Colitis
35. A Meta-Analysis of the Placebo Rates of Remission and Response in Clinical Trials of Active Ulcerative Colitis
36. 132 - Inflammatory Bowel Disease
37. Association of 6-Thioguanine Nucleotide Levels and Inflammatory Bowel Disease Activity: A Meta-Analysis
38. American Gastroenterological Association Institute Technical Review on Corticosteroids, Immunomodulators, and Infliximab in Inflammatory Bowel Disease
39. American Gastroenterological Association Institute Medical Position Statement on Corticosteroids, Immunomodulators, and Infliximab in Inflammatory Bowel Disease
40. Serious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT Registry
41. The Impact of Increased Body Mass Index on the Clinical Course of Crohn’s Disease
42. Infliximab in Ulcerative Colitis
43. Infliximab in Fistulizing Crohn's Disease
44. Chemoprevention: Risk Reduction with Medical Therapy of Inflammatory Bowel Disease
45. 913b THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY
46. Tu1741 EFFICACY AND SAFETY OUTCOMES IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS STRATIFIED BY ETHNICITY AND RACE: A POOLED ANALYSIS OF DATA FROM GEMINI 1, VARSITY, AND VISIBLE 1
47. Tu1732 SAFETY OF UPADACITINIB IN ULCERATIVE COLITIS: LONG-TERM DATA FROM THE PHASE 3 OPEN-LABEL EXTENSION STUDY (U-ACTIVATE)
48. Su1812 OUTCOMES OF PATIENTS WITH CROHN'S DISEASE WHO DEVELOP ECTOPIC PREGNANCY: A NATIONAL COHORT ANALYSIS
49. Su1814 PATIENT AGE PREDICTS INFECTION RISK IN INFLAMMATORY BOWEL DISEASE: A NATIONAL POPULATION COHORT STUDY
50. Su1809 PREGNANCY OUTCOMES IN CROHN'S DISEASE PATIENTS EXPOSED TO CERTOLIZUMAB PEGOL: SAFETY DATA FROM THE SECURE REGISTRY
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.